Peptide specificity of alloreactive CD4 positive T lymphocytes directed against a major histocompatibility complex class I disparity

Transplantation

Volumn 62, Issue 10, 1996, Pages 1485-1491

  Ossevoort, Miriam A ^a,b   De Bruijn, Marloes L H ^a   Van Veen, Karin J H ^a   Martin Kast, W ^c   Melief, Cornelis J M ^a,d  

^a LEIDEN UNIVERSITY   (Netherlands)

^b BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIGEN BINDING; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

EID: 0029826685     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199611270-00017     Document Type: Article

References (50)

1. Nathenson SG, Geliebter J, Pfaffenbach GM, Zeff RA. Murine major histocompatibility complex class-I mutants. Annu Rev Immunol 1986; 4: 471.
2. Bjorkman PJ, Saper MA, Samraouri B, Bennet WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987; 329: 506.
3. Brown JH, Jardetzky TS, Gorga JC, et al. The three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993; 364: 33.
4. Engelhard VH. Structure of peptides associated with class I and class II MHC molecules. Annu Rev Immunol 1994; 12: 181.
5. Germain RN. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 1994; 76: 287.
6. Lechler R, Lombardi G. Structural aspects of allorecognition. Curr Opin Immunol 1991; 3: 715.
7. Sherman LA, Chattopadhyay S. The molecular basis of allorecognition. Annu Rev Immunol 1993; 11: 385.
8. Shoskes DA, Wood KJ. Indirect presentation of MHC antigens in transplantation. Immunol Today 1994; 1: 32.
9. Cattopadhyay S, Theobald M, Biggs J, Sherman LA. Conformational differences in major histocompatibility complex-peptide complexes can result in alloreactivity. J Exp Med 1994; 179: 213.
10. Hunt HD, Munitz TI, Pease LR. Alloreactive cytotoxic T lymphocytes recognize epitopes determined by both the a helices and β sheets to the class I peptide binding site. J Exp Med 1992; 175: 821.
11. Essaket S, Fabron J, De Preval C, Thomsen M. Corecognition of HLA-A1 and HLA-DPw3 by a human CD4+ alloreactive T lymphocyte clone. J Exp Med 1990; 172: 387.
12. Schendel DJ. On the peptide model of allorecognition: cytotoxic T lymphocytes recognize an alloantigen encoded by two HLA-linked genes. Hum Immunol 1990; 27: 229.
13. Maryanski JL, Pala P, Cerottini JC, Corradin G. Synthetic peptides as antigens and competitors in recognitions by H-2-restricted cytolytic T cells specific for HLA. J Exp Med 1988; 167: 1391.
14. Heath WR, Sherman LA. Cell-type-specific recognition of allogeneic cells by alloreactive T cells: a consequence of peptide-dependent allorecognition. Eur J Immunol 1991; 21: 153.
15. b by alloreactive cytotoxic T lymphocytes. Nature 1989; 341: 749.
16. Man S, Salter RD, Engelhard VH. Role of endogenous peptide in human alloreactive cytotoxic T cell responses. Int Immunol 1992; 4: 367.
17. Clayberger C, Rosen M, Parham P, Krensky AM. Recognition of an HLA public determinant (Bw4) by human allogeneic cytotoxic T lymphocytes. J Immunol 1990; 144: 4172.
18. Grandea III AG, Bevan MJ. A conservative mutation in a class I MHC molecule outside the peptide binding groove stimulates responses to self peptides. J Immunol 1993; 151: 3981.
19. Parham P, Clayberger C, Zorn SL, Ludwig DS, Schoolnick GK, Krensky AM. Inhibition of alloreactive cytotoxic T lymphocytes by peptides from the alpha2 domain of HLA-A2. Nature 1987; 325: 625.
20. Schneck J, Munitz T, Coligan JE, Maloy WL, Margulies DH, Singer A. Inhibition of allorecognition by an H-2Kb-derived peptide is evidence for a T-cell binding region on a major histocompatibility complex molecule. Proc Natl Acad Sci USA 1989; 86: 8516.
21. b gene shows a cluster of seven nucleotide differences. Proc Natl Acad Sci USA 1983; 80: 2007.
22. b mutant skin allograft differing at class I MHC. Nature 1986; 322: 829.
23. b mutants. J Exp Med 1980; 151: 993.
24. Bjorkman PJ, Saper MA, Samraoui B, Bennet WS, Strominger JL, Wiley DC. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987; 329: 512.
25. Bluestone JA, Kaliyaperumal A, Jameson S, Miller S, Dick II R. Peptide-induced changes in class I heavy chains alter allorecognition. J Immunol 1993; 151: 3943.
26. Schumacher TNM, Van Bleek GM, Heemels MT, et al. Synthetic peptide libraries in the determination of T cell epitope and peptide binding specificity of class I molecules. Eur J Immunol 1992; 22: 1405.
27. Van Bleek GM, Nathenson SG. The structure of the antigen-binding groove of major histocompatibility complex class I molecules determines specific selection of self-peptides. Proc Natl Acad Sci USA 1991; 88: 11032.
28. Rammensee HG, Friede T, Stevanovic S. MHC ligands and peptide motifs: first listing. Immunogenetics 1995; 41: 178.
29. De Waal LP, Kast WM, Melvold RW, Melief CJM. Regulation of the cytotoxic T lymphocyte response against Sendai virus analyzed with H-2 mutants. J Immunol 1983; 130: 1090.
30. b-restricted ovalbumin determinant. Eur J Immunol 1990; 20: 2431.
31. Geysen HM, Meloen RH, Barteling SJ. Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. Proc Natl Acad Sci USA 1984; 81: 3998.
32. Van der Zee R, Van Eden W, Meloen RH, Noordzij A, Van Embden JDA. Efficient mapping and characterization of a T cell epitope by simultaneous synthesis of multiple peptides. Eur J Immunol 1989; 19: 43.
33. Gausepohl G, Kraft M, Boulin Ch, Frank RW. Automatic multiple peptide synthesis with BOP activation. In: Rivier JE, Marshall GR ed. 11th American peptide symposium. Leiden: ESCOM, 1990: 1003.
34. Geluk A, Bloemhoff W, De Vries RRP, Ottenhof THM. Binding of a major T cell epitope of mycobacteria to a specific pocket within HLA-DRw17 (DR3) molecules. Eur J Immunol 1992; 22: 107.
35. Dialynas DP, Quan ZS, Wall KA, et al. Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to human Leu3/T4 molecule. J Immunol 1983; 131: 2445.
36. Sarmiento M, Glasebrook AL, Fitch FW. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement. J Immunol 1980; 125: 2665.
37. Kast WM, Boog CJP, Roep BO, Voordouw AC, Melief CJM. Failure or success in restoration of virus-specific cytotoxic T lymphocyte response defects by dendritic cells. J Immunol 1988; 140: 3186.
38. Tindle RW, Fernando GJP, Sterling JC, Frazer IH. A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc Natl Acad Sci USA 1991; 88: 5887.
39. ba mutant involve recognition of syngeneic Ia molecules. Nature 1983; 302: 429.
40. Rudensky YA, Preston-Hurburt P, Hong SC, Barlow A, Janeway CA Jr. Sequence analysis of peptides bound to MHC class II molecules. Nature 1991; 353: 622.
41. Rudensky YA, Preston-Hurburt P, Al-Ramadi BK, Rothbard J, Janeway CA Jr. Truncation variants of peptides isolated from MHC class II molecules suggest sequence motifs. Nature 1992; 359: 429.
42. Sprent J, Schaefer M, Lo D, Korngold R. Properties of purified T cell subsets. II In vivo responses to class I vs. class II H-2 differences. J Exp Med 1986; 163: 998.
43. Asano Y, Komuro T, Tada T. Synergistic T-T cell interaction present in alloreactivity: determination of "MLR helper" T cell subsets. Int Immunol 1990; 2: 1203.
44. Mizuochi T, Ono S, Malek TR, Singer A. Characterization of two distinct primary T cell populations that secrete interleukin 2 upon recognition of class I or class II major histocompatibility antigens. J Exp Med 1986; 163: 603.
45. Chen BP, Madrigal A, Parham P. Cytotoxic T cell recognition of an endogenous class I HLA peptide presented by a class II HLA molecule. J Exp Med 1990; 170: 779.
46. Benham A, Fabre JW. Fine specificity of peptide determinants for indirect T cell recognition of class I MHC alloantigens. Transplantation 1994; 58: 1236.
47. Benichou G, Fedoseyeva E, Lehmann PV, et al. Limited T cell response to donor MHC peptides during allograft rejection. J Immunol 1994; 153: 938.
48. Gallon L, Watschinger B, Murphy B, Akalin E, Sayegh MH, Carpenter CB. The indirect pathway of allorecognition: the occurence of self-restricted T cell recognition of allo-MHC peptides early in acute renal allograft rejection and its inhibition by conventional immunosuppression. Transplantation 1995; 59: 612.
49. Benham AM, Sawyer GJ, Fabre JW. Indirect T cell allorecognition of donor antigens contributes to the rejection of vascularized kidney allografts. Transplantation 1995; 59: 1028.
50. De Waal LP, Nathenson SG, Melief CJM. Direct demonstration that cytotoxic T lymphocytes recognize conformational determinants and not primary amino acid sequences. J Exp Med 1983; 158: 1720.